# Glaukos Stock: Second J-Code Rewrites Risk Math

> Glaukos' second J-code drug launch reshapes risk math for investors.
- Title: Glaukos Stock: Second J-Code Rewrites Risk Math · Seekingalpha
- Summary: Glaukos' second J-code drug launch reshapes risk math for investors. Glaukos' iDose TR and Epioxa drugs drive 50% YoY sales growth with Medicare coverage…
- Keywords: glaukos, idose tr, epioxa, medicare, j-code, nyse, net sales, gross margin, corneal health, money, business, Stock
- Source: Seekingalpha — https://seekingalpha.com/article/4953195-glaukos-the-second-j-code-rewrites-the-risk-math
- Author: Equity Eagle
- Published: 2026-10-10T03:42:31+00:00
- Read time: 1 min
- Topics: glaukos, idose tr, epioxa, medicare, j-code, nyse, net sales, gross margin, corneal health, money, business
## Glaukos Transition
Glaukos shifts from single-product reimbursement to diversified ophthalmic pharmaceutical platform with two J-coded drugs.
## Q2 Sales Growth
Q2 net sales grew 50% YoY to $185.6M driven by iDose TR and Epioxa launch with 85% non-GAAP gross margin.
## 2026 Sales Guidance
Management raised 2026 net sales guidance to $680, 700M with iDose TR sales expected at $275, 280M.
## Key takeaway

Glaukos' iDose TR and Epioxa drugs drive 50% YoY sales growth with Medicare coverage risks and strong margins.